PharmaMar to Commercialize PM1183 with Trade Name of Zepsyre

PharmaMar, a world-leading biopharmaceutical company, has announced that PM1183 (lurbinectedin), its third molecule of marine origin and analogue of Yondelis, will receive the trade name of Zepsyre.

Zepsyre is currently undergoing development for the treatment of solid tumours. This promising agent is currently in final stage for platinum-resistant ovarian cancer and small cell lung cancer. Both the European Medicines Agency (EMA) and the Food and Drug Administration (FDA), as regulatory agencies, require the trade name to be unique and is part of the evaluation and approval process before marketing the product.

After the positive results presented during the last ESMO and ASCO meetings about BRCA 2 -associated metastatic breast cancer and endometrial cancer, respectively, PharmaMar will initiate a pivotal phase III study in each indication.

"We trust in the potential of Zepsyre as a therapeutic alternative due to its novel mechanism of action and the antitumoral activity observed in all clinical trials for different type of tumors," says Luis Mora, Managing Director Oncology Business Unit at PharmaMar.

Zepsyre is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is essential for the transcription process that is over-activated in tumors with transcription addiction.